SB 20989th Legislature (2025)
Relating to the creation of the Texas technology and innovation program.
Progress
- Introduced
- In committee
- Passed one chamber Not yet
- Passed legislature Not yet
- Sent to governor Not yet
- Became law Not yet
What this bill would cost
-
Fiscal note: Introduced
Estimated cost to the state’s general budget: $1,909,059 over two years, through August 31, 2027.
Five-year impact on state general revenue Fiscal year 2026 2027 2028 2029 2030 General revenue −$1.0 million −$893,380 −$932,477 −$896,738 −$936,000 Savings/(Cost) from General Revenue Fund 1 −$1.0 million −$893,380 −$932,477 −$896,738 −$936,000 Change in Number of State Employees from FY 2025 $6 $6 $6 $6 $6 Negative amounts are costs to the state; positive amounts are savings or revenue. From the Legislative Budget Board’s fiscal note.
Fiscal notes are prepared by the state’s budget staff and reflect the bill as written at the time.
Committee hearings
-
March 24, 2025
Senate Economic Development Committee · Left pending in committee
Testified: 3 for, 0 against, 0 on (neutral) · Registered without testifying: 12 for, 0 against, 0 on
- Organizations for
- AstraZeneca, Biotechnology Innovation Organization, Dallas County, Dallas Regional Chamber, GlaxoSmithKline GSK, Greater Houston Partnership, and 6 more
-
April 2, 2025
Senate Economic Development Committee · Reported favorably w/o amendments
Source: Texas Legislature (Texas Legislative Council). Witness lists show how many people took each position and the organizations they represented; people speaking for themselves are counted but not named here.
Committee votes
- Senate Economic Development · Out of committee 5 aye, 0 nay
Companion bills: HB 1268 by Button, Identical
Bill analyses: Introduced
Legislative history
-
Senate
Not again placed on intent calendar
-
Senate
Placed on intent calendar
-
Senate
Not again placed on intent calendar
-
Senate
Placed on intent calendar
-
Senate
Not again placed on intent calendar
-
Senate
Co-author authorized
-
Senate
Placed on intent calendar
-
Senate
Co-author authorized
-
Senate
Co-author authorized
-
Senate
Committee report printed and distributed
-
Senate
Reported favorably w/o amendments
-
Senate
Vote taken in committee
-
Senate
Considered in public hearing
-
Senate
Left pending in committee
-
Senate
Testimony taken in committee
-
Senate
Considered in public hearing
-
Senate
Scheduled for public hearing on . . .
-
Senate
Referred to Economic Development
-
Senate
Read first time
-
Senate
Filed
-
Senate
Received by the Secretary of the Senate